The PennZone

  • Home
  • Non-profit
  • Music
  • Marketing
  • Books
  • Entertainment
  • Health
  • Automotive
  • Business

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • Jacombs Tickets Partners with UEFA to Offer Champions League Tickets
  • Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Keystone Consulting Engineers Marks Next Chapter of Growth with Refreshed Brand
  • AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
  • DayPass llega a ChatGPT y Claude
  • DayPass launches in ChatGPT and Claude
  • Renkeer Water Quality Sensors Support Efficient Operation of AI Liquid Cooling Systems

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
  • BitTitan Accelerates Large-Scale Document Migrations with MigrationWiz
  • Clearnetworx Deploys netElastic vBNG, CGNAT And netVision To Power Fiber Expansion Across Colorado's Western Slope
  • Glenn Strange - Iconic Horror actor of Universal Studios Frankenstein's Monster Fame Honored
  • Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
  • Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
  • Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
  • Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
  • Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
  • Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1
  • Vegan Kingz Expands Direct-Import Wholesale Lineup to Help Commercial Kitchens Cut Ingredient Costs
  • Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
  • Acuvance Survey Finds ERP Integration Remains a Key Challenge as Healthcare Organizations Prepare for AI
  • Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
  • Ten Ten Ten Announces Alento, Its Initiative to Help Independent Primary Care Thrive
  • JFAB Consulting to Celebrate New Brand with Private VIP Event at Acrisure Stadium
  • Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society

Popular on PennZone

  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers - 113
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
  • Can Government Operate Better Through Innovation?
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • Keystone Consulting Engineers Expands into Brodheadsville, Strengthening Regional Engineering
  • World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA

Similar on PennZone

  • Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
  • Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us